+
Sun Pharma & Moebius Reveal Promising MM-II Osteoarthritis Data
ECONOMY & POLICY

Sun Pharma & Moebius Reveal Promising MM-II Osteoarthritis Data

Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA).

MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism.

Key Publication Highlights:

Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more

Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.

Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA). MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism. Key Publication Highlights: Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.

Next Story
Real Estate

No glass boxes!

India is moving away from the ‘glass box’ syndrome, all-glass façades that were widely used in commercial buildings in the last two decades but came at a significant environmental cost given the country’s predominantly hot and humid climate. Poor thermal performance, excessive heat gain and dependency on mechanical cooling systems made buildings with glass façades energy guzzlers and significantly increased their carbon footprint.That said, it’s important to be aware that “glass is not the enemy,” points out Heena Bhargava, Architect, Architecture Discipline. “How it ..

Next Story
Infrastructure Transport

Why do pavements fail?

India’s highways continue to expand at a healthy pace. But conversations on the surface quality of highways are growing louder because major deficiencies and black spots continue to be identified, and they are cause for concern.“Road surface roughness causes vehicle vibrations that, in turn, can affect the performance of drivers,” explains Dr V K Gahlot, Road Safety Auditor, Centre for Research and Sustainable Development (CfRSD). “Continuous exposure may induce fatigue, a contributory factor to road accidents. Road surface roughness also affects the vehicle operating cost...

Next Story
Infrastructure Urban

APAC Logistics Rents Fall for First Time Since 2020

Logistics rents across the Asia-Pacific region declined 0.4% year-on-year in H1 2025, marking the first annual drop since 2020, according to Knight Frank’s Logistics Highlights H1 2025 report. Despite global trade tensions and cautious occupier sentiment, India emerged as a standout performer, driven by robust manufacturing momentum and supply chain recalibration.Regional Trends and DivergenceWhile rents largely remained stable across most markets, regional differences became more pronounced:Mainland China continued to see rental declines, though the pace of decline moderated to 12.8% YoY, s..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?